Back to the program

Topic-Contributed Paper Session

Use and Challenges with surrogate, composite endpoints and Generalized pairwise comparisons for accelerating drug development

Thu, Aug 10, 10:30 AM

Amit BhattacharyyaChair

Biopharmaceutical Section

4 Presentations

The use of surrogate endpoints to manage the risk and accelerate drug development in oncology

10:35 AM - 10:55 AM

Bethany Gill (AstraZeneca)

Co-authors: Xian Zhou (AstraZeneca)

Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials

10:55 AM - 11:15 AM

Bo Huang (Pfizer)

What about the overall effect? The 'Net treatment Benefit' as a measure to consider the associations between hierarchical outcomes

11:15 AM - 11:35 AM

Vaiva Deltuvaite-Thomas (IDDI)

The DOOR is Open: Pragmatic Benefit:Risk Evaluation Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes

11:35 AM - 11:55 AM

Toshimitsu Hamasaki (George Washington University)

Co-authors: Scott Evans (George Washington University)

↑